Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women
Pierre D. Delmas(Inserm), Claus Christiansen(VA Eastern Colorado Health Care System), Bruce Mitlak(Radius Health (United States)), Anne-Catherine Ravoux(Inserm), William J. Huster(Eli Lilly (United States)), Nina H. Bjarnason(Center for Clinical & Basic Research), Aarti S. Shah(Eli Lilly (United States)), Michael Draper(Eli Lilly (United States))
Cited by 1,648
Related Papers
The diagnosis of osteoporosis
|Journal of Bone and Mineral Research|1994|3.9k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.4k
Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes
|Nature Genetics|2006|2.3k
Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis
|Journal of Bone and Mineral Research|2004|1.2k
The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women
|Osteoporosis International|2007|1.2k